StreetAlpha
13F holdings · Q3 2026

Aisling Capital Management

New York, NY · files as Aisling Capital Management LP
Know the moment Aisling Capital Management filesYou follow Aisling Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 12, 2026Next filing due Feb 15, 2027CIK 1766721

Aisling Capital Management reported 14 stocks worth $299M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are BBIO (67.9%), SNDX (8.3%) and CMPS (7.2%). Compared with Q2 2026, the fund added to CMPS and VTVT and trimmed BBIO, BCAX and SRRK.

Latest filing: what Aisling Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
0 new2 added3 trimmed0 sold outBought about $4M · sold about $101M
New 0

None

Added 2
Trimmed 3
Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$299M−36.5% vs last quarter
Stocks held140 new · 0 sold out
Top 5 weight93.0%very concentrated
Turnover35%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
BBIO
Bridgebio Pharma Inc
$203M67.9%3.1M−1.5M (−33%)8 of 8
2
SNDX
Syndax Pharmaceuticals Inc
$24.8M8.3%1.3MNo change8 of 8
3
CMPS
Compass Pathways PLC
$21.6M7.2%1.7M+300K (+21%)8 of 8
4
GLUE
Monte Rosa Therapeutics Inc
$18.6M6.2%1.6MNo change8 of 8
5
BCAX
Bicara Therapeutics Inc
$10.2M3.4%549K−20K (−4%)8 of 8
6
URGN
Urogen Pharma Ltd
$4.4M1.5%108KNo change4 of 8
7
BBOT
Bridgebio Oncology Therapeut
$4.1M1.4%1MNo change5 of 8
8
EPRX
Eupraxia Pharmaceuticals Inc
$3M1.0%325KNo change3 of 8
9
BMEA
Biomea Fusion Inc
$2.7M0.9%2MNo change8 of 8
10
ACRS
Aclaris Therapeutics Inc
$2.3M0.8%434KNo change8 of 8
🔒 4 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 8 quarters
$282MQ4 '24
$288MQ1 '25
$360MQ2 '25
$456MQ3 '25
$479MQ4 '25
$476MQ1 '26
$472MQ2 '26
$299MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 12, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Aisling Capital Management 13F FAQ

What does Aisling Capital Management own?

Aisling Capital Management reported 14 stocks worth $299M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are BBIO (67.9%), SNDX (8.3%) and CMPS (7.2%). The table above lists every position in the filing (the top 10 without an account).

What did Aisling Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 0 new positions, 2 added to, 3 trimmed and 0 sold out.

When will Aisling Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Aisling Capital Management's portfolio worth?

The Q3 2026 filing reports $299M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.